Of the 212 patients who were verified to have RCC and treated with any ICI therapy, 94 patients had sufficient electronic medical record (EMR) documentation and treatment with single-agent anti-PD-1 or PD-L1 therapy to assess response (Figure 1A). This evidence concerns the gene CD274 and renal cell carcinoma.